Biotech Archives - Page 132 of 795

1 minute read

Inspira Announces Plans To Launch And Target Single-Use Disposable Blood Oxygenation Kit For A New Disposable Perfusion Market Opportunity; The Kit, Anticipated To Be Submitted For U.S. FDA Authorization In 2025

January 9, 9:42 AM

The kit is being designed for the INSPIRA™ ART device series and is intended to be compatible with various life support machines sold in the market RA'ANANA, Israel, Jan. 9, 2024 /PRNewswire/ -- Inspira

IINN

2 minute read

Simulations Plus Embarks On Collaboration With Northeastern University And The TIM Company Through New FDA Grant

By Benzinga Newsdesk

January 9, 9:41 AM

Partnership aims to integrate experimental data and PBPK modeling to identify key formulation factors to accelerate modified-release product developmentSimulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling

SLP

4 minute read

SELLAS Life Sciences Receives FDA Fast Track Designation For SLS009 For Treatment Of Relapsed/Refractory Acute Myeloid Leukemia And Provides Updated Data For Phase 2a Study Of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia Patients

By Benzinga Newsdesk

January 9, 9:36 AM

- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive with Significant Antileukemic Effect Observed in 87.5% of Evaluable Patients -- First Enrolled

SLS

3 minute read

Quest Diagnostics And Ultima Collaborate To Scale Ultima’s Technology In Fast-Growing Minimal Residual Disease And Whole Genome Sequencing

By Benzinga Newsdesk

January 9, 9:23 AM

Goal to combine Ultima's highly sensitive, low-cost technology with Quest's oncology expertise and national scale in order to improve patient access, affordability and outcomesUltima Genomics, a developer of a

DGX

1 minute read

TFF Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For Presentation At The 44th Annual International Society For Heart And Lung Transplantation 2024 Meeting

By Benzinga Newsdesk

January 9, 9:13 AM

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology

TFFP

1 minute read

NGM Bio Announces Clinical Data From Trial Of NGM707 In Advanced Solid Tumors And Outlines Evolved Strategy For Aldafermin And NGM120

By Benzinga Newsdesk

January 9, 9:05 AM

Encouraging findings in heavily pretreated patients in multiple solid tumor indications, including MSS colorectal cancer (CRC), in ongoing Phase 1 Part 1b study evaluating NGM707, a dual ILT2/ILT4 antagonist antibody, in

NGM

2 minute read

Pfizer’s Aggressive Stance In Obesity Drugs: CEO Albert Bourla Confirms Bold Bet Despite Prior Drug Hurdles

By Vandana Singh

January 9, 8:42 AM

Monday, at the JP Morgan Healthcare Conference, Pfizer Inc (NYSE: PFE) CEO Albert Bourla expressed that the company is determined to move forward in the burgeoning

GSK

2 minute read

GSK Boosts Its Asthma Product Portfolio With Over $1B Deal For Aiolos Bio

By Vandana Singh

January 9, 8:26 AM

GSK plc (NYSE: GSK) has agreed to acquire Aiolos Bio Inc

GSK

3 minute read

Ironwood Announces Publication In The Lancet Gastroenterology & Hepatology Of New Linaclotide Phase III Data In Children And Adolescents Aged 6-17 Years With Functional Constipation

By Benzinga Newsdesk

January 8, 11:59 PM

– Newly published data highlights additional efficacy endpoints from trial –– Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years with functional constipation

IRWD

2 minute read

Er-Kim Announces Exclusive Distribution Agreement With Ascendis Pharma A/S To Commercialize 3 Endocrinology Disease Treatments Across Central & Eastern Europe And Turkey

By Benzinga Newsdesk

January 8, 11:58 PM

Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies, today announced it has entered into an exclusive distribution agreement with Danish Company Ascendis Pharma A/S

ASND